{"meta":{"query_hash":"7bfd0db550be","filters":{"venue":"Kidney Cancer"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7bfd0db550be","api":"https://metacan.xera.ac/api/v1/cohort?venue=Kidney+Cancer"},"results":[{"id":"W2605821659","doi":"10.3233/kca-160002","title":"Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)","year":2017,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"Foundation Medicine; Astellas Pharma; Eisai; National Comprehensive Cancer Network; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Renal cell carcinoma; Medicine; Chromophobe cell; Oncology; Targeted therapy; Cancer; Internal medicine; Clear cell","score_opus":0.05602898733680911,"score_gpt":0.3205884367928813,"score_spread":0.2645594494560722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605821659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97398746,0.0037397635,0.0003108741,0.0002989,0.000020881642,0.000044806,0.020069879,0.000018105004,0.001509377],"genre_scores_gemma":[0.9785539,0.0008941852,0.00021201686,0.00011752615,0.000028049297,0.000025173049,0.020061327,0.0000107507685,0.00009721022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980565,0.0005539221,0.0002623231,0.000344299,0.0006106284,0.0001723201],"domain_scores_gemma":[0.9955727,0.00087400543,0.0021126117,0.00034794124,0.00067623815,0.0004164542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024189143,0.00015086806,0.00054062187,0.0010136666,0.00024679294,0.0009190404,0.00034947973,0.00023953631,0.0007187726],"category_scores_gemma":[0.005628949,0.00009627504,0.00052556203,0.0020885356,0.00022858207,0.00045491286,0.00073826674,0.00038747097,0.00015944829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079835195,0.00003855138,0.98588735,0.00014449455,0.0003758567,0.000050603074,0.000085950756,0.0003294223,0.00016096598,0.000095369374,0.002315185,0.009717843],"study_design_scores_gemma":[0.00006982948,0.00027655708,0.9940308,0.0000991757,0.00037597129,0.0004890919,0.0002348585,0.0006126694,0.00029206128,0.000082337174,0.003422368,0.000014306826],"about_ca_topic_score_codex":0.0061649997,"about_ca_topic_score_gemma":0.011748309,"teacher_disagreement_score":0.0061649997,"about_ca_system_score_codex":0.0008590651,"about_ca_system_score_gemma":0.0007321729,"threshold_uncertainty_score":0.012792647},"labels":[],"label_agreement":null},{"id":"W2741346996","doi":"10.3233/kca-170010","title":"Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward","year":2017,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"ECOG-ACRIN Cancer Research Group; European Association of Urology; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Perioperative; Nephrectomy; Oncology; Adjuvant therapy; Internal medicine; Clinical trial; Surgery; Immunotherapy; Chemotherapy; Kidney; Cancer","score_opus":0.07852159444762236,"score_gpt":0.39968673167374524,"score_spread":0.3211651372261229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741346996","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023465259,0.36039555,0.017359547,0.5653896,0.01775401,0.00036589557,0.00023031278,0.00034844578,0.014691446],"genre_scores_gemma":[0.19418924,0.47369143,0.05848129,0.23331651,0.03070982,0.0008181901,0.0006234681,0.00023966085,0.007930455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824154,0.00092659047,0.00011890561,0.00019055158,0.00026306877,0.00025930142],"domain_scores_gemma":[0.9934551,0.0026777023,0.0006307588,0.000398923,0.0011799369,0.0016575198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008859385,0.00047033053,0.0007734992,0.00049851305,0.00066736504,0.0033332298,0.0012151418,0.0022123177,0.004167938],"category_scores_gemma":[0.0066611306,0.00019070094,0.001196709,0.000542185,0.0019743934,0.0048947707,0.0018610833,0.0077906363,0.0012141222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016819789,0.0020066614,0.003331697,0.0028124764,0.00017903282,0.00033794018,0.00051240745,0.001197874,0.004356458,0.039172087,0.0686126,0.87579864],"study_design_scores_gemma":[0.002114935,0.009359027,0.009533665,0.0063550496,0.00043021762,0.0015907219,0.0019557015,0.0020142302,0.005274979,0.06966347,0.89148283,0.00022521251],"about_ca_topic_score_codex":0.0011221124,"about_ca_topic_score_gemma":0.004066983,"teacher_disagreement_score":0.008859385,"about_ca_system_score_codex":0.0013470165,"about_ca_system_score_gemma":0.006016739,"threshold_uncertainty_score":0.046853423},"labels":[],"label_agreement":null},{"id":"W2787239315","doi":"10.3233/kca-170020","title":"Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)","year":2018,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Axitinib; Sorafenib; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Temsirolimus; Proportional hazards model; Targeted therapy; Retrospective cohort study; Urology; Surgery; Cancer; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","score_opus":0.05521137413412077,"score_gpt":0.3092914079217557,"score_spread":0.25408003378763494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787239315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8199022,0.00905683,0.00043198222,0.0007184168,0.000046995352,0.000114052265,0.16730508,0.000067593974,0.0023568904],"genre_scores_gemma":[0.85892713,0.001682964,0.0004751321,0.00025634386,0.000043136333,0.00007722337,0.13821045,0.000024633982,0.0003029857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965012,0.0009766852,0.0005832195,0.00061692117,0.001026626,0.0002953067],"domain_scores_gemma":[0.9849781,0.0032418242,0.0074067307,0.0013822301,0.0020288366,0.00096219894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046041864,0.00032664934,0.0010609633,0.0018675686,0.00027179235,0.0015464511,0.0007301985,0.000452062,0.0015874185],"category_scores_gemma":[0.010791997,0.00013471245,0.0012220116,0.0050863097,0.00017796372,0.00058639917,0.0011991223,0.0004893647,0.00041564548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002076155,0.000059214133,0.9760453,0.00047100414,0.0009756306,0.00007194723,0.000069624606,0.00096169225,0.00012401337,0.00008657348,0.0068816864,0.012177189],"study_design_scores_gemma":[0.00025972992,0.0002592521,0.9871683,0.000228933,0.0008065538,0.00029125655,0.00018784557,0.0018115913,0.0002688365,0.000059394886,0.008634985,0.000023410208],"about_ca_topic_score_codex":0.023210065,"about_ca_topic_score_gemma":0.024236884,"teacher_disagreement_score":0.023210065,"about_ca_system_score_codex":0.001536076,"about_ca_system_score_gemma":0.0015064777,"threshold_uncertainty_score":0.04614997},"labels":[],"label_agreement":null},{"id":"W2996252896","doi":"10.3233/kca-190075","title":"Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and <sup>99m</sup> Tc-MDP Bone Scan in a Prospective Clinical Trial","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Renal cell carcinoma; Radiology; PET-CT; Clinical trial; Nuclear medicine; Computed tomography; Oncology; Internal medicine","score_opus":0.021984695673895376,"score_gpt":0.3223716724288983,"score_spread":0.3003869767550029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996252896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446046,0.003768898,0.00020936556,0.00023721058,0.000051309635,0.00068082404,0.00015616405,0.000016565837,0.000419231],"genre_scores_gemma":[0.99653673,0.0013172554,0.0005400433,0.00022994791,0.00012554466,0.00067879097,0.00038092484,0.0000052836467,0.00018550105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813217,0.0013232152,0.00013617497,0.00019513645,0.00011858413,0.000094721116],"domain_scores_gemma":[0.9973013,0.0009365628,0.00076361373,0.00016936375,0.00014549584,0.00068365375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048280465,0.0010345215,0.0019482602,0.00031243527,0.00033443797,0.001125103,0.0006512878,0.0014638919,0.0012392994],"category_scores_gemma":[0.0036074657,0.00048308683,0.0014354447,0.00050078053,0.00076577923,0.0008021107,0.00036806188,0.0015788601,0.00037119322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93037105,0.0050181323,0.033509552,0.00037788483,0.001100368,0.0001124577,0.00008554678,0.00070241105,0.0032327722,0.000045859906,0.0001970886,0.025246914],"study_design_scores_gemma":[0.49797744,0.38967574,0.10050451,0.00014337733,0.0028196846,0.0005411721,0.000096562035,0.0035203025,0.0026120802,0.00017226461,0.0018759115,0.000060994375],"about_ca_topic_score_codex":0.00051995844,"about_ca_topic_score_gemma":0.0010545106,"teacher_disagreement_score":0.0048280465,"about_ca_system_score_codex":0.0006568459,"about_ca_system_score_gemma":0.00093884167,"threshold_uncertainty_score":0.025533497},"labels":[],"label_agreement":null},{"id":"W2997361961","doi":"10.3233/kca-190077","title":"Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Dosing; Medicine; Toxicity; Vascular endothelial growth factor; Cancer; Drug; Tyrosine-kinase inhibitor; Adjuvant; Oncology; VEGF receptors; Pharmacology; Internal medicine","score_opus":0.0229485505792703,"score_gpt":0.3077115109704465,"score_spread":0.2847629603911762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997361961","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20190386,0.7505059,0.024837915,0.0061812573,0.0007520215,0.0004895915,0.00016615356,0.00019819675,0.014965118],"genre_scores_gemma":[0.6227665,0.34500822,0.024894817,0.00198287,0.0015653591,0.00035090058,0.00020932002,0.00011879863,0.0031033107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999212,0.0003940996,0.00010746079,0.000056822173,0.00019393738,0.00003567702],"domain_scores_gemma":[0.9990773,0.0004511634,0.00035182646,0.000030935033,0.000056126908,0.000032676027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018965463,0.00023098016,0.0007935317,0.00040285717,0.00018746466,0.00057359884,0.00044064596,0.00025906166,0.00054778805],"category_scores_gemma":[0.0020894054,0.00010346328,0.00058948743,0.00031678373,0.00021397117,0.00038166228,0.00023630337,0.0006662716,0.00015722819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002120043,0.00039873976,0.0047205593,0.0026012447,0.0002881874,0.00019271178,0.0001334896,0.0064471653,0.012355652,0.0015876708,0.003108814,0.96604574],"study_design_scores_gemma":[0.004847916,0.051256657,0.1393866,0.005877248,0.0033574414,0.011773859,0.00054682617,0.016672108,0.063055456,0.014549009,0.68834513,0.0003318196],"about_ca_topic_score_codex":0.00032617757,"about_ca_topic_score_gemma":0.0012494185,"teacher_disagreement_score":0.0018965463,"about_ca_system_score_codex":0.0009218244,"about_ca_system_score_gemma":0.0005554296,"threshold_uncertainty_score":0.010030031},"labels":[],"label_agreement":null},{"id":"W3014903654","doi":"10.3233/kca-190076","title":"First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Renal cell carcinoma; Medicine; Oncology; Nivolumab; Cancer research; Internal medicine; Immunotherapy; Cancer","score_opus":0.06481327969497024,"score_gpt":0.33528547229551825,"score_spread":0.270472192600548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014903654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008434472,0.9981147,0.000086104985,0.00015850503,0.00006744132,0.00020493695,0.00032230842,0.0000057261027,0.00019687516],"genre_scores_gemma":[0.014269882,0.98398834,0.0003830488,0.0004243609,0.000073533934,0.00046746343,0.00027638665,0.0000030905019,0.00011390072],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99685353,0.0011282108,0.0010238133,0.0002685899,0.000596169,0.00012969231],"domain_scores_gemma":[0.9908818,0.005434606,0.0022758718,0.000115538074,0.0011267973,0.00016548156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043364633,0.0012343039,0.0074941744,0.0059183193,0.00043699352,0.0014738399,0.0015053593,0.0014003264,0.005143279],"category_scores_gemma":[0.014180536,0.0006260665,0.007310719,0.0066964882,0.00046777798,0.0013513183,0.00085250865,0.00089277717,0.00031321694],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024578837,0.00001697315,0.00048189942,0.9659614,0.011343207,0.00005947097,0.000065677996,0.000086916574,0.000118955606,0.00008942657,0.0012116607,0.020318594],"study_design_scores_gemma":[0.00065349997,0.0004542007,0.005119664,0.8166679,0.15856163,0.00038629997,0.00017578392,0.00014571748,0.00019043715,0.00021056825,0.017393671,0.000040564857],"about_ca_topic_score_codex":0.006465398,"about_ca_topic_score_gemma":0.020712301,"teacher_disagreement_score":0.0074941744,"about_ca_system_score_codex":0.0023753322,"about_ca_system_score_gemma":0.007540786,"threshold_uncertainty_score":0.022933662},"labels":[],"label_agreement":null},{"id":"W3135371333","doi":"10.3233/kca-210110","title":"Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; St Joseph's Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Centre hospitalier universitaire de Québec; London Health Sciences Centre; Alberta Health Services; McMaster University; University of Manitoba; Juravinski Cancer Centre; Université Laval; University of Alberta","funders":"Genentech; Ipsen; Astellas Pharma; Eisai; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Exelixis; GlaxoSmithKline","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Kidney cancer; Internal medicine; Cancer; Oncology; Tyrosine-kinase inhibitor; Population; Urology; Surgery; Gastroenterology","score_opus":0.027269369056509476,"score_gpt":0.27533422388788525,"score_spread":0.24806485483137578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135371333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761595,0.0043101767,0.00019574763,0.001397757,0.000021584368,0.00019297547,0.013825231,0.000029228278,0.0038677738],"genre_scores_gemma":[0.98715323,0.001735955,0.00043301517,0.0005668967,0.000041021867,0.0000714459,0.009304246,0.000016295537,0.0006777945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974859,0.0006929868,0.00031466686,0.00028649298,0.0009513324,0.0002686667],"domain_scores_gemma":[0.9873076,0.0025163894,0.004607245,0.000428931,0.0031311414,0.0020086202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003523847,0.00018557576,0.00045356384,0.00062088756,0.0006410662,0.0010674486,0.0005389472,0.00040318182,0.002470037],"category_scores_gemma":[0.01176773,0.00013358373,0.00039313984,0.002401715,0.00049845915,0.0005802106,0.00078983704,0.00043848276,0.0004563196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084734745,0.00045253662,0.912169,0.0007259302,0.00030170506,0.0003663078,0.001642796,0.0010379928,0.00065524323,0.00015428774,0.01143365,0.062587075],"study_design_scores_gemma":[0.0009284683,0.001727033,0.9789514,0.00015848146,0.00026172097,0.00039067742,0.0011789023,0.0010825627,0.00056153507,0.000059016103,0.014640738,0.00005953362],"about_ca_topic_score_codex":0.3911007,"about_ca_topic_score_gemma":0.40637636,"teacher_disagreement_score":0.6088993,"about_ca_system_score_codex":0.007190917,"about_ca_system_score_gemma":0.0065983646,"threshold_uncertainty_score":0.7776485},"labels":[],"label_agreement":null},{"id":"W3186123873","doi":"10.3233/kca-210116","title":"Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Nephrectomy; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunohistochemistry; Oncology; Proportional hazards model; Internal medicine; Kidney cancer; Cancer; Metastasis; Clear cell; Pathology; Kidney","score_opus":0.014673006305765644,"score_gpt":0.2340668076723973,"score_spread":0.21939380136663164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186123873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995852,0.00020172463,0.00005011645,0.000018921191,0.0000018767563,0.0000013951033,0.00004205066,0.0000020718599,0.000096587144],"genre_scores_gemma":[0.99982184,0.000038721308,0.000026384041,0.000005935444,0.000005302687,0.000001808267,0.00005878932,5.744488e-7,0.000040618073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998518,0.00003163786,0.000013654177,0.000034066547,0.00004061483,0.00002813624],"domain_scores_gemma":[0.999332,0.00013294259,0.00032205952,0.000023096847,0.000069418966,0.000120413744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023546,0.00014039133,0.00022209149,0.00041617223,0.00022816008,0.00030417685,0.0001622205,0.00023524952,0.0011450818],"category_scores_gemma":[0.0010874926,0.00010674863,0.00017668415,0.00040598036,0.0001963432,0.00021779347,0.00020192678,0.00029841872,0.00012400534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025110185,0.000015333038,0.99645495,0.000009523642,0.000022444781,0.00013570626,0.000024031055,0.00005984042,0.0015690763,0.000008440569,0.000058218666,0.0013913899],"study_design_scores_gemma":[0.000007708891,0.00009317679,0.9984847,0.0000021917513,0.000026301555,0.00064869446,0.000049914488,0.00026621987,0.00029434316,0.000019507555,0.00010523332,0.0000020584805],"about_ca_topic_score_codex":0.0009417905,"about_ca_topic_score_gemma":0.0014269074,"teacher_disagreement_score":0.0011450818,"about_ca_system_score_codex":0.00019651403,"about_ca_system_score_gemma":0.00016054475,"threshold_uncertainty_score":0.003830731},"labels":[],"label_agreement":null},{"id":"W4200092447","doi":"10.3233/kca-210117","title":"Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Exelixis; University of Texas Southwestern Medical Center; Burroughs Wellcome Fund","keywords":"Cabozantinib; Medicine; Disease; Renal cell carcinoma; Cancer research; Oncology; Internal medicine; Urology; Pharmacology","score_opus":0.015818733380308158,"score_gpt":0.2664854274567906,"score_spread":0.25066669407648245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200092447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983615,0.00048593665,0.0002840429,0.000046711637,0.000002740365,0.00003081597,0.000051706502,0.0000054224834,0.00073111855],"genre_scores_gemma":[0.9995499,0.00007789269,0.00019667955,0.00003372758,0.000006368681,0.0000074047916,0.00005492742,0.0000014271604,0.00007167118],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99941003,0.00018434116,0.00007990148,0.00012638411,0.00014116711,0.000058112106],"domain_scores_gemma":[0.9985876,0.00051401625,0.000552221,0.0001102697,0.00008676498,0.00014916147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010922769,0.00015758195,0.00030462083,0.00019190939,0.00033808223,0.00035580833,0.00019678251,0.00021195384,0.0007447781],"category_scores_gemma":[0.0016397858,0.00007267088,0.00042219344,0.0002820502,0.0002452647,0.00023132795,0.00027399894,0.0004944293,0.0001135918],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006870414,0.0016556837,0.8877087,0.00020615644,0.00039403682,0.0031001172,0.00037269777,0.003048661,0.015959352,0.0001408025,0.00042516526,0.08011811],"study_design_scores_gemma":[0.0004899287,0.015308706,0.9582416,0.000027129257,0.0003116078,0.008601553,0.00016429834,0.0037518137,0.010723232,0.00014891496,0.0022077293,0.000023490511],"about_ca_topic_score_codex":0.0012134237,"about_ca_topic_score_gemma":0.0022348908,"teacher_disagreement_score":0.0012134237,"about_ca_system_score_codex":0.0011659646,"about_ca_system_score_gemma":0.00040210423,"threshold_uncertainty_score":0.008459747},"labels":[],"label_agreement":null},{"id":"W4396814048","doi":"10.3233/kca-230025","title":"Patient Selection for Active Surveillance for Small Renal Masses: A Systematic Review of the Literature","year":2024,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concordance; Systematic review; Meta-analysis; Comorbidity; MEDLINE; Internal medicine; Cochrane Library; Oncology; Intensive care medicine","score_opus":0.03505213495838975,"score_gpt":0.3362367575413587,"score_spread":0.3011846225829689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396814048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028853428,0.99504095,0.00023007336,0.00034295986,0.00009878049,0.00048112532,0.00067523593,0.000010299034,0.00023531297],"genre_scores_gemma":[0.053862676,0.94168305,0.0013037025,0.0009801374,0.00013032295,0.001264936,0.0006526387,0.000010175074,0.00011230309],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9875306,0.0046126293,0.0052101845,0.00086198404,0.0015342445,0.0002504147],"domain_scores_gemma":[0.9513904,0.03717976,0.007597271,0.0006010913,0.002850754,0.0003806844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012233718,0.0013737764,0.008904601,0.009549707,0.00059270713,0.0022997698,0.0016989473,0.0016486455,0.0037492283],"category_scores_gemma":[0.052848455,0.00085403345,0.009418945,0.009833733,0.0009266426,0.0018967909,0.0013337885,0.0009280342,0.00023687477],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028709284,0.000012504077,0.00206123,0.9600885,0.015959008,0.00012357358,0.00022808848,0.00007964834,0.00012106551,0.00010774425,0.0008973667,0.020034295],"study_design_scores_gemma":[0.00044466424,0.00024881773,0.007948825,0.8348639,0.14638694,0.0004997168,0.00043851492,0.00011084001,0.00016891463,0.00029675695,0.008549024,0.000043075015],"about_ca_topic_score_codex":0.0062974524,"about_ca_topic_score_gemma":0.018933862,"teacher_disagreement_score":0.012233718,"about_ca_system_score_codex":0.002980531,"about_ca_system_score_gemma":0.009669646,"threshold_uncertainty_score":0.064698875},"labels":[],"label_agreement":null},{"id":"W4401252649","doi":"10.3233/kca-240005","title":"Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy","year":2024,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Calgary","funders":"Ipsen","keywords":"Cabozantinib; Renal cell carcinoma; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Internal medicine; Cancer research; Cancer; Receptor","score_opus":0.016508258337435484,"score_gpt":0.2769879987711579,"score_spread":0.2604797404337224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401252649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683386,0.0010741713,0.000108434804,0.000134797,0.000012777905,0.000039440296,0.0012773795,0.000003130453,0.00051601225],"genre_scores_gemma":[0.99826896,0.00019841512,0.00010173755,0.0000658891,0.00002130165,0.000034731915,0.0012391659,0.000002035734,0.00006777027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722326,0.001135462,0.0004441104,0.0005100738,0.00042865967,0.00025839714],"domain_scores_gemma":[0.9873094,0.0021422864,0.0087618865,0.00040211243,0.0006469867,0.00073727366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034869171,0.00020449307,0.00070331665,0.0007544535,0.00039797783,0.0011794306,0.00043217602,0.00054866436,0.0011566448],"category_scores_gemma":[0.010130067,0.00021498486,0.0010135198,0.0013500666,0.0004348155,0.0010388116,0.0006398704,0.00096956163,0.00022722139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002100986,0.00019356323,0.9936009,0.00008792075,0.00035817397,0.00011886843,0.00013837035,0.00030002627,0.00007640232,0.00004779471,0.00025140197,0.0027255728],"study_design_scores_gemma":[0.00018312137,0.0019334345,0.99481285,0.000055357043,0.00028291077,0.0006067182,0.00027345464,0.0006401721,0.0001455468,0.000099720724,0.0009388976,0.00002788631],"about_ca_topic_score_codex":0.0024287144,"about_ca_topic_score_gemma":0.0026299325,"teacher_disagreement_score":0.0034869171,"about_ca_system_score_codex":0.0012978313,"about_ca_system_score_gemma":0.0005588876,"threshold_uncertainty_score":0.018440783},"labels":[],"label_agreement":null}]}